#rt-pcr device

[pathologylab]

The PAN Pathogen Panel used at Genes2Me is an all-in-one PCR amplicon that allows the pathogenic microbial nucleic acids with no errors. The Panel can identify viruses, bacteria, fungi, parasites, and pathogenic microorganisms. Genes2Me has taken the Pan Pathogen testing to a next level by accelerating the accuracy that can drastically decrease the time of detection. This can effectively change the entire pathogen testing processes to a great deal.

[marketingreportz]

Companion Diagnostics Market - Forecast(2024 - 2030)

 Companion Diagnostic Market Overview:

The Harvard University, while addressing the risk associated with reactions of new drugs prescription, has stated some overwhelming facts. According to their findings, even properly prescribed drugs causes about 1.9 million hospitalizations a year and about 128,000 people die from drugs prescribed to them.[1] Such epidemic condition is being tailgated by the need of safe and effective and specific use of the drug. Owing to such demands, companion diagnostic drug market is poised for exponential growth. Companion diagnostics is an in-vitro diagnostic tool that assists physicians in optimizing treatment decisions for their patients and is crucial for myriad of cancer and other therapies. Riding on the back of economic burden of global healthcare and with abundant potential to restrict the liability, companion diagnostic market size is estimated to be $2,950 million as of 2018.

Inquiry Before Buying

Companion Diagnostic Market Outlook:

Companion diagnostic (CDx) is a diagnostic test used as an associate to a therapeutic drug to regulate its applicability to an individual person. It involves multiple monitoring methods including immunohistochemistry (IHC), polymerase chain Reaction (PCR), in-situ hybridization (ISH), real-time PCR (RT-PCR), and gene sequencing. The companion diagnostics uses technologies such as molecular biology technique, drug and diagnostic technology, and oncology therapy for the treatment of colorectal cancer, breast cancer, and other chronic diseases.

 An acute analysis of the region-wise companion diagnostic market share concluded with reckoning North America as the most lucrative market for CDx. This region with cutting-edge healthcare technology in the United States and Canada generates 41% of the global companion diagnostic market demand for alarming need for cancer diagnosis and treatment. According to the American Cancer Society, prostate cancer is the most common cancer among males (19%), followed by lung (14%) and colorectal (9%) cancers and among females, breast (30%), lung (12%), and colorectal (8%) cancers are the most common. Increasing instances of cancer along with neurological disorders, infectious diseases, Hepatitis A is augmenting the North American companion diagnostic market.

Companion diagnostic market with abundant potential as an effective tool for personalized medicine has found a tremendous scope of application in pharmaceuticals, laboratories, research institutes and hospitals. Hospital as an end-user industry is the leading segment progressing with an application CAGR of 12.5% going through 2025. Hospitalized patients account for a total of 2.74 million serious adverse drug reactions. Each CDx test is specifically designed to be corresponding with an exact drug. Such tests can also save significant hospital expenditure by targeting specific patients with the most effective therapy.

Request Sample

 Companion Diagnostic Market Trends and Growth Drivers:

·         The necessity for personalized therapeutics for the cumulative geriatrics population and the increasing figure of diagnostics centers in both the developed and developing economies is predominant to determine profits in the global companion diagnostics market.

·         FDA had issued "Guidance for Industry: In Vitro Companion Diagnostic Devices," to assist syndicates recognize the necessity for companion diagnostics at an initial stage in the drug development procedure and to strategize for co-development of the drug and companion diagnostic test.

 On July 15, 2016, FDA introduced the draft regulation, "Principles for Co-development of an In Vitro Companion Diagnostic Device with a Therapeutic Product." This guidance text is envisioned to be a practical guide to support therapeutic product promoters and IVD sponsors in evolving a therapeutic product and an associated IVD companion diagnostic. The scientific progressions in the in-situ hybridization and automated silver-enhanced in-situ hybridization (SISH) for the monitoring of genes is trending in the global companion diagnostics market.

Schedule a Call

 Companion Diagnostic Market Players Perspective:

Some of the key players influencing the global market are:-  Abbott Laboratories, Agilent Technologies, biomerieux, Bio-Genex Laboratories, Danaher Corporation, GE Healthcare, Myriad Genetics, Inc., QIAGEN N.V., R-Biopharm AG, and Roche Diagnostics.

In April 2017, Abbott acquired Alere for a new price of about $5.3 billion. Alere is the global leader in point of care diagnostics focused on the areas of infectious disease, molecular, cardiometabolic and toxicology. The collective business will offer the biggest point of care menu of infectious disease, molecular, cardiometabolic and toxicology testing. Abbott's platforms will be expanded to comprise benchtop and rapid strip tests.

Buy Now

 Companion Diagnostic Market Research Scope:

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the companion diagnostic market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the various diagnostics in companion diagnostic market, and their specific advantages.

[businessmarketreports]

The Evolution of the COVID-19 Test Devices Market: From Early Pandemic to Present Day

The COVID-19 pandemic triggered a rapid and unprecedented surge in demand for diagnostic testing devices. As the pandemic unfolded, the market for COVID-19 tests underwent a remarkable transformation, characterized by rapid innovation, technological advancements, and increased global production capacity.

Buy the Full Report for More Insights on the COVID-19 Tests Market Forecast, Download a Free Sample Report

Early Pandemic: A Rush for Testing Devices

Initial Shortages: The early stages of the pandemic were marked by severe shortages of testing devices, particularly in regions with high infection rates. This scarcity hindered efforts to contain the virus and understand its spread.

Rapid Innovation: In response to the urgent need, manufacturers, researchers, and governments worldwide accelerated the development of new testing technologies, including RT-PCR, antigen tests, and rapid point-of-care (POC) tests.

Scaling Up Production: Global efforts were made to scale up the production of testing devices, leveraging existing manufacturing capabilities and establishing new facilities.

Advancements in Testing Technologies

RT-PCR Tests: Reverse-transcriptase polymerase chain reaction (RT-PCR) tests remained the gold standard for COVID-19 diagnosis, offering high sensitivity and specificity. However, their complexity and turnaround time limited their widespread use.

Antigen Tests: Rapid antigen tests, while less sensitive than RT-PCR, provided faster results and were more suitable for mass testing and screening purposes.

Point-of-Care Tests: POC tests, often lateral flow immunoassays, offered rapid results at the point of care but faced challenges in terms of sensitivity and specificity.

Saliva-Based Tests: The development of saliva-based testing simplified sample collection and made testing more accessible to the general public.

Market Expansion and Competition

Increased Production Capacity: Global manufacturers expanded their production capacities to meet the surging demand for COVID-19 tests.

New Market Entrants: Many new companies entered the market, driven by the lucrative opportunities presented by the pandemic.

Intense Competition: The market became highly competitive, with manufacturers vying for market share through price reductions, technological advancements, and improved turnaround times.

Challenges and Future Trends

Variant Challenges: The emergence of new COVID-19 variants, such as Omicron, posed challenges for testing devices, requiring adaptations to maintain accuracy.

Long-Term Demand: As the pandemic evolves, the long-term demand for COVID-19 tests remains uncertain, potentially impacting market dynamics.

Dual-Use Technologies: Some testing technologies, particularly those developed for COVID-19, have the potential to be repurposed for other infectious diseases, creating new market opportunities.

Home Testing: The increasing availability of at-home COVID-19 tests is changing the landscape of testing, empowering individuals to take control of their health.

The COVID-19 pandemic has significantly transformed the testing devices market, driving rapid innovation, increased production capacity, and a surge in demand. As the pandemic evolves, the market is likely to continue adapting to new challenges and opportunities, shaping the future of infectious disease testing.

[trendingreportz]

Cancer Testing Screening Market - Forecast(2024 - 2030)

Cancer Testing Screening Market Overview

Cancer Testing Screening Market size is projected to reach $220.66 billion by 2027 and is expected to grow at a CAGR of 6.4% during the forecast period 2022-2027. Cancer Testing and Screening are vital procedures for aid in the early detection of cancer before symptoms occur. It lowers the risk of malignant cells growing abnormally and lowers the person's mortality rates. Each type of cancer has a screening test that can help spot cancer early on. There is increasing adoption of cancer screening tests, particularly in countries with the highest cancer rates. The improved research and development activities coupled with the increasing public awareness of cancer diseases are all predicted to create a new window of opportunities in the global cancer Testing screening market. However, COVID-19 has restrained the market growth. The lack of adequate supplies needs for more service providers added to the crises, thereby restraining the market growth.

Cancer Testing Screening Market Report Coverage

The report: “Cancer Testing Screening Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Cancer Testing Screening Market.

By Type: Diagnostics, Screening. By Cancer Type: Respiratory System Cancer, Leukemia, Myeloma and Lymphoma, Skin Cancer, Abdominal/Digestive System Cancer, Genital Cancer, Oral Cancer, Urinary System Cancer, Endocrine System Cancer, Breast Cancer, Others. By Technique: Imaging, Biopsy, Genomic and Molecular Tests (Next Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, Others. By Product Type: Molecular Diagnostics, Companion Diagnostics. By Stage: Terminal, Stage 0-4, Prognosis, Other Staging System. By Gender: Male, Female. By Geography: Americas (U.S, Canada, Brazil, Rest of Americas), Europe (U.K, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, and South Korea), and Rest of the World (Middle East, Africa).

Request Sample

Key Takeaways

Geographically, The Americas Cancer Testing Screening market accounted for the highest revenue share in 2021, followed by Europe. This is owing to the steady rise of Lung and Prostate Cancer cases in both regions which are being driven by the adoption of unhealthy lifestyles such as excessive alcohol consumption and smoking.

The increasing number of cancer cases around the world is unfortunate. However, it is beneficial to the cancer screening industry. The industry is also being propelled forward by Increased research and development (R&D) to develop effective cancer treatments and early detection. Innovative technologies including positron emission mammography, spectroscopy-enhanced colonoscopy, and hyperpolarization MRI, among others, are improving screening efficiency.

Cancer Testing Screening Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Cancer Testing Screening Market report.

Cancer Testing Screening Market Segment Analysis – By Cancer Type

The Cancer Testing Screening Market based on Cancer Type can be segmented into Respiratory System Cancer, Leukemia, Myeloma, and Lymphoma, Skin Cancer, Abdominal/Digestive System Cancer, Genital Cancer, Oral Cancer, Urinary System Cancer, Endocrine System Cancer, Breast Cancer, and Others. Abdominal/Digestive system cancer had the largest share in the cancer testing screening market in 2021 and is expected to grow at a CAGR of 5.9% owing to the rise in consumption of processed food and alcohol. Additionally, the increase in the global geriatric population has generated demand for imaging devices for early detection and treatment of Abdominal cancer, thereby driving the segment. According to the Organization of the United Nations, the proportion of people aged 65 and up in the global population climbed from 6% in 1990 to 9% in 2019. By 2050, that percentage is expected to climb to 16%, implying that one in every six individuals on the planet is predicted to be 65 or older.

Inquiry Before Buying

Cancer Testing Screening Market Segment Analysis – By Technique

The Cancer Testing Screening Market based on the Technique can be segmented into Imaging, Biopsy, Genomic and Molecular Tests (Next Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, and Others. Biopsy technique dominated the Cancer testing screening Market in 2021 and is expected to grow at a CAGR of 6.2%. This is owing to its high accuracy during Cancer Diagnosis. Other Diagnostic advances, such as imaging techniques, have increased demand for cancer testing and screening. Imaging has become an important aspect of cancer detection and diagnosis, with recent advancements in tumor imaging technologies improving the diagnosis of five common cancers, including breast, lung, prostate, and colorectal cancers.

Cancer Testing Screening Market Segment Analysis – By Geography

The Cancer Testing Screening Market based on Geography can be segmented into Americas, Europe, Asia-Pacific, and the Rest of the World. Americas region dominated the cancer screening/testing market in 2021 with a market share of 41% and is growing at a CAGR of 4.5% during the forecast period 2022-2027. This is owing to the high rate of new cancer cases each year along with increased awareness amongst the masses.

 However, Asia Pacific is set to be the fastest-growing segment with a CAGR of 11% during the forecast period 2022-2027. This is owing to the growing rate of endocrine, abdominal, leukemia, myeloma, and lymphoma cancers in the Asia Pacific region. 

Schedule a Call

Cancer Testing Screening Market Drivers

Growing Number Of Cancer Screening Awareness Campaigns To Raise Awareness About The Importance Of Early Detection Of Breast Cancer Is To Drive Market Growth

Several governmental and commercial groups are launching various campaigns to raise awareness about the importance of early detection of breast cancer, the second most frequent cancer among women in the United States. Breast Cancer Diagnostics Market Growth Depends on Cancer Awareness Campaigns. Nations around the globe have initiated various Cancer Screening Awareness Campaigns to encourage young people to make these life-saving behaviors part of their daily routine. For example, Breast cancer campaigns, Cervical cancer awareness campaigns, Protect Your Skin campaigns, Ovarian cancer awareness campaigns and Colorectal cancer awareness campaigns are among the few impacting the growth of the cancer screening and diagnostics market. For instance, the 'Be Clear on Cancer campaign has substantially increased the number of referrals under the 2WW rule. This has increased demands on both resources (59% more tests) and finance. Cost per cancer detected rose by 27% with no increase in funding to support the increased activity.

Technological Advancements And Automation In Cancer Testing And Screening Is To Fuel Service Demand

Cancer testing has become more accurate and user-friendly as a result of technological developments and automation, which has aided industry growth. Novel screening technologies have largely been adopted owing to their ability to increase tumor detection rates. Additionally, the cancer testing & screening market is likely to be driven by the approval of novel biomarkers and increased R&D spending. The key players in the market are increasingly investing in AI-based imaging biomarkers. For instance, Brainomix has invested $21.2 million for the development of an AI platform that automates validated imaging biomarkers to improve both diagnosis and treatment decisions to build on the proven success of the company's tech platform in stroke and enable value-generating pharmaceutical partnerships. Proteomics and genomics are two OMICS technologies that will propel the cancer testing & screening industry forward.

Cancer Testing Screening Market Challenges

High Cost Of Cancer Diagnosis And Increased Financial Burden To Hamper The Market Growth

Cancer has a significant financial impact on patients and their families. Today, the estimated 16.1 million cancer patients face annual out-of-pocket medical expenses that are 61% higher than those who do not have cancer. Cancer patients had higher out-of-pocket costs than non-cancer patients, with high-deductible health plans having the greatest out-of-pocket costs. According to a report by the National Coalition of Cancer Survivorship 47% of cancer patients reported financial burden in cancer care.

Buy Now

Cancer Testing Screening Industry Outlook

Product Launch, Collaboration, and Acquisitions key strategies adopted by players in the Cancer Testing Screening Market. In 2020, the Cancer Testing Screening Market share is consolidated by the top ten players present in the market. In the Cancer Testing Screening Market, the top 10 companies are-

DiaSorin S.p.A

Immunodiagnostic Systems Holdings Ltd

Epigenomics AG

Quest Diagnostics Inc.

F. Hoffmann-La Roche Ltd

VolitionRX Limited

Abbott Laboratories

QIAGEN GmbH

Siemens Healthineers AG

Becton, Dickinson, and Company

Recent Developments

In January 2022, Siemens Healthineers, through its subsidiary Varian entered into a ten-year strategic partnership with Oulu University Hospital in Finland, to build a comprehensive digital, diagnostic and therapeutic ecosystem that addresses the entire cancer treatment pathway. Siemens will supply a technology and services package to Oulu University Hospital that includes cancer imaging and radiation therapy equipment, software solutions for enhanced workflow and decision support, and related support services.

In February 2022, Becton, Dickinson, and Company acquired Cytognos, a company specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection, and immune monitoring research for blood diseases. The acquisition enables BD to enhance chronic illness management by increasing its offering of blood cancer diagnostics, immunological assessment tests, and informatics.

In October 2021, Roche entered into a collaboration with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology. Under the agreement, the companies are to jointly develop an embedded image analysis workflow for pathologists, which can benefit cancer patients through more precise diagnosis. 

[wellnessweb]

Microfluidics Market Size and Regulatory Impact

The Microfluidics Market size was estimated at USD 28.71 billion in 2022 and is expected to reach USD 72.10 billion by 2030 at a CAGR of 12.2% during the forecast period of 2023-2030.The microfluidics market is experiencing rapid growth, driven by advancements in healthcare, biotechnology, and pharmaceuticals. This innovative technology, which manipulates small volumes of fluids through channels with dimensions in the micrometer range, offers unparalleled precision and efficiency in applications such as point-of-care diagnostics, drug delivery systems, and lab-on-a-chip devices. The market's expansion is further fueled by the increasing demand for personalized medicine, the rise of miniaturized medical devices, and substantial investments in research and development. As microfluidics continues to revolutionize various sectors, it promises to enhance analytical capabilities, reduce costs, and improve patient outcomes globally.

Get Sample Copy Of This Report @ https://www.snsinsider.com/sample-request/3848

Market Scope & Overview 

The market research report highlights the important regulatory organizations as well as the important international rules and regulations put in place to regulate this industry. Interviews, questionnaires, and the observation of well-known industry experts are all used in the main study. The market research for Microfluidics Market includes market size predictions, verifiable data from reliable sources, and in-depth qualitative analysis. The predictions are supported by an established research methodology. In order to develop the market analysis, primary and secondary data were used.

The research uses the Ansoff Matrix and Porter's Five Forces model to carry out a complete market analysis. An innovative method for examining and assessing a company's position that combines a market performance score with an industry position score is called a competitive quadrant. The Microfluidics Market  study also discusses the sector's regulatory environment, which will help you make a wise decision.

Market Segmentation Analysis

By Application

Medical/Healthcare

PCR & RT-PCR

Gel Electrophoresis

Microarrays

ELISA

Others

Non-medical

By Material

Silicon

Glass

Polymer

polydimethylsiloxane (PDMS)

Others

By Technology

Lab-on-a-chip

Medical

Non-Medical

Organs-on-chips

Medical

Non-Medical

Continuous Flow Microfluidics

Medical

Non-Medical

Optofluidics And Microfluidics

Medical

Non-Medical

Acoustofluidics And Microfluidics

Medical

Non-Medical

Electrophoresis And Microfluidics

Medical

Non-Medical

Russia-Ukraine Conflict Impact Analysis

Recent market research on the target market discusses how the crisis between Russia and Ukraine has affected that market. The Microfluidics Market  research focuses on both the emerging prospects and the significant problems that the market is currently experiencing as a result of these disagreements.

Regional Outlook

Numerous aspects, including the financial performance of the prior year, growth objectives, innovation score, new product releases, investments, market share growth, and others are all taken into consideration when conducting research on different areas of the Microfluidics Market  throughout the world.

Competitive Analysis

The top market participants are carefully investigated, with information on their histories, SWOT analyses, most recent successes, and corporate objectives included. Every aspect of the market is looked at, with a focus on important players such market leaders, followers, and entrants. By offering a thorough comparative analysis of the major players in the Microfluidics Market  based on their offerings, prices, financial standing, product portfolios, growth strategies, and geographic reach, the report serves as a buyer's guide for investors.

Key Reasons to Purchase Microfluidics Market  Report

To track the development of the worldwide market competition, keep an eye on new product releases, collaborations, market expansions, and acquisitions.

Insights into the company's goods, applications, important areas and countries, market size, historical data, and forecast estimates.

Conclusion

The data and figures in the report will assist multinational corporations in defining, clarifying, and evaluating their product sales volume, value, and market share, as well as market competition, SWOT analysis, and long-term growth strategies.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Flash Chromatography Market Size

Cystic Fibrosis Market Size

Cancer Biopsy Market Size

Glaucoma Therapeutics Market Size

Genomics Services Market Size

[rnomics]

Biosensors, Vol. 13, Pages 988: Detection of Reverse Transcriptase LAMP-Amplified Nucleic Acid from Oropharyngeal Viral Swab Samples Using Biotinylated DNA Probes through a Lateral Flow Assay

This study focuses on three key aspects: (a) crude throat swab samples in a viral transport medium (VTM) as templates for RT-LAMP reactions; (b) a biotinylated DNA probe with enhanced specificity for LFA readouts; and (c) a digital semi-quantification of LFA readouts. Throat swab samples from SARS-CoV-2 positive and negative patients were used in their crude (no cleaning or pre-treatment) forms for the RT-LAMP reaction. The samples were heat-inactivated but not treated for any kind of nucleic acid extraction or purification. The RT-LAMP (20 min processing time) product was read out by an LFA approach using two labels: FITC and biotin. FITC was enzymatically incorporated into the RT-LAMP amplicon with the LF-LAMP primer, and biotin was introduced using biotinylated DNA probes, specifically for the amplicon region after RT-LAMP amplification. This assay setup with biotinylated DNA probe-based LFA readouts of the RT-LAMP amplicon was 98.11% sensitive and 96.15% specific. The LFA result was further analysed by a smartphone-based IVD device, wherein the T-line intensity was recorded. The LFA T-line intensity was then correlated with the qRT-PCR Ct value of the positive swab samples. A digital semi-quantification of RT-LAMP-LFA was reported with a correlation coefficient of R2 = 0.702. The overall RT-LAMP-LFA assay time was recorded to be 35 min with a LoD of three #RNA copies/µL (Ct-33). With these three advancements, the nucleic acid testing-point of care technique (NAT-POCT) is exemplified as a versatile biosensor platform with great potential and applicability for the detection of pathogens without the need for sample storage, transportation, or pre-processing. https://www.mdpi.com/2079-6374/13/11/988?utm_source=dlvr.it&utm_medium=tumblr

[daangene]

AGS8830 Real-Time PCR Detection System

Daan's real-time PCR detection system, the AGS8830, combines multiple optimized design features to provide outstanding performance and reliable results. There are two models: AGS8830-8 and AGS8830-16, which can proceed 8 or 16 samples per run. Together with Daan's 2019-nCoV fast PCR kits, this real-time pcr machine can get results in 35 minutes.

AGS8830 Real-Time PCR Detection System Features Fast: get results in 35 minutes together with DA099X/DA107X.

Throughput: 8 or 16.

Accurate temperature control: advanced semiconductor refrigeration technology.

User-friendly: LCD screen/ Humanized operation interface.

Large data storage: store more than 1000 files.

Portable: 5.5kg.

Result out-put: directly display on the screen or transferred by USB. Specification Of AGS8830 Real-Time PCR Detection System Sample size 8×0.1mL/0.2mL Centrifuge tube (5μL-100µL) 16×0.1mL/0.2mL Centrifuge tube (5μL-100µL) Heating rate（average） ≥3.1℃ Cooling rate（average） ≥2.7℃ Temperature range： 30-100℃ Fluorescence channel F1: FAM, SYBR GreenI, etc.    F2: HEX, VIC, JOE, etc. F3: ROX, TEXAS RED, etc.     F4: Cy5, etc. Dimension(mm)（L×W×H） 300×260×180 Weight (Kg) 5.5

[sanpdr1994]

Point-of-care Molecular Diagnostics Market Sales, Revenue and Market Share by Regions Analysis and Forecasts to 2032

Per the point-of-care molecular diagnostics market survey by Future Market Insights (FMI), the market is forecasted to move forward at an average pace and register a CAGR of 8% from 2022 to 2032.

Many current POC diagnostics are based on lateral flow immunoassay technology, and these instruments use antibodies to detect the presence of an analyte, such as cancer biomarkers, in a short period and thus, having the effect of spurring the point-of-care molecular diagnostics market growth to a large extent. As per the point-of-care molecular diagnostics market report, the demand for point-of-care molecular diagnostics is on a surge owing to the growing trend toward preventive medicine. This is considered to shape the point-of-care molecular diagnostics future trends to a large extent.

According to United Nations data, the number of older adults has steadily increased for decades. As a result of this demographic shift, the prevalence of various chronic diseases is rising, thereby facilitating the adoption of point-of-care molecular diagnostics devices. The study finds that current cancer diagnostic methods are invasive (for example, cystoscopy, which involves inserting a hollow tube/cystoscope installed with a lens into the urethra and bladder to diagnose cancer). However, less invasive methods, such as point-of-care molecular tests, can be available for point-of-care cancer diagnostics, broadening the point-of-care molecular diagnostics opportunities.

Though most of the industries’ overall sales of molecular diagnostics dwindled steeply due to the COVID-19 pandemic and the use of molecular diagnostic methods for COVID-19 testing, it had a positive impact on the point-of-care molecular diagnostics market size. As countries gradually slacken their restrictions on movement, there is a resurgence in testing numbers. Aside from vaccines and therapeutic drugs, there is an increasing demand for the development of more precise and simple testing technologies and the expansion of testing structures.

Key Takeaways

The assays and kits segment is expected to account for a significant chunk of the POC molecular diagnostics market based on the product type. The market growth of this segment is being driven by the widespread purchase of these products’ POC diagnostic devices as a result of their frequent usage. The RT-PCR segment is expected to dominate the point-of-care molecular diagnostics market in terms of technology, owing to the increasing use of RT-PCR in proteomics, genomics, and COVID-19 testing and the availability of portable, easy-to-use POC devices.

The respiratory diseases segment is projected to lead the POC molecular diagnostics market on account of the shift of concentration by key players on various strategies for developing advanced point-of-care diagnostics devices.

By end-use, the hospital bedside segment is expected to witness the most significant point-of-care molecular diagnostics market share due to the rising adoption of advanced instruments in these settings and rapid investments in hospital infrastructure by the public and private sectors in emerging countries. The Asia Pacific region is expected to proliferate due to the expansion of key market players, a lack of sophisticated central laboratory point-of-care molecular testing services, and the potential cost-effectiveness of POC molecular diagnosis.

“The North American market is expected to be at the forefront of the point-of-care molecular diagnostics market, attributable to the United States’ emerging trends in point-of-care molecular diagnostics market such as well-organized health-care system. In addition, the system promotes research and development. These policies encourage foreign players to enter the United States and the North American market. As a result, many global market players are present in this region, and the market is projected to flourish as high demand is met by the presence of global players in the region.” opines an FMI researcher.

Competitive Landscape

The top point-of-care diagnostics companies are developing most point-of-care molecular diagnostic tests and have established their market position by investing more in research and developing a better distribution system.

The entry of new players challenges the semi-consolidated market and may result in intense competition during the forecast period.

Furthermore, due to increased awareness, the Asia-Pacific region is seeing the emergence of some minor players, which aided the point-of-care molecular diagnostics market growth.

Danaher Corporation (US), Alere Inc. (US), Quidel Corporation (US), Biocartis Group NV (Belgium), bioMérieux SA (France), Thermo Fisher Scientific (US), Mesa Biotech Inc. (US), F. Hoffmann-La Roche Ltd., and Meridian Bioscience Inc. (US) are the critical point-of-care diagnostic companies profiled in the global POC molecular diagnostics market.

Recent developments in the point-of-care molecular diagnostics market are as follows:

The World Health Organization (WHO), Africa Centers for Disease Control and Prevention (Africa CDC), the Bill & Melinda Gates Foundation, the Clinton Health Access Initiative (CHAI), the Foundation for Innovative New Diagnostics (FIND), and the Global Fund constituted a global partnership. Today, the organization announced the launch of the COVID-19 rapid test in low and middle-income countries. Mylab Discovery Solutions has collaborated with Hemex Health, the United States company, to develop next-generation diagnostic solutions for coronavirus and another point-of-care diagnostic testing.

Point-of-care Molecular Diagnostics Market Key Segments

By Product & Service:

Assays & kits Instruments & Analyzers Software & Services

By Technology:

RT-PCR INAAT Other technologies

By Application:

Respiratory Diseases Sexually Transmitted Diseases Hospital-acquired Infections Cancer Hepatitis Gastrointestinal Disorders Other Applications

By End User:

Physicians’ Offices Hospitals & ICUs Research Institutes Other End Users

[allthebrazilianpolitics]

Brazilian researchers patent two new Covid-19 tests

[Image description: healthcare worker performing a covid-19 nasal swap test on a patient.]

Researchers at the Federal University of São Carlos have patented two new Covid-19 testing technologies. Both are highly sensitive and, if produced on a large scale by partner companies, they would enable the mass testing of Brazil’s population — one of the major bottlenecks in the country’s pandemic response.

One of the technologies involves an electrochemical sensor allowing for the quantitative analysis of spike proteins in the patient’s saliva, dispensing the need for nasal swabs. “This is a fast and portable test model. It is highly sensitive and is similar to devices that measure glucose levels of diabetics. An electrochemical sensor captures the spike protein and the result can be accessed in a matter of minutes, via a smartphone app,” researcher Ronaldo Censi Faria told Agência Fapesp.

The other test developed by the team detects the RNA of the virus in saliva with a precision similar to that of RT-PCR tests, considered to be the gold standard for diagnosing Covid-19. However, it is a faster and more cost-effective method, as it uses fewer reagents.

Before filing the patents, the two tests were used on saliva samples from patients treated at hospitals in São Carlos and São Paulo, both reaching a sensitivity level greater than 90 percent.

Source.

[pathologylab]

The PAN Pathogen Panel used at Genes2Me is an all-in-one PCR amplicon that allows the pathogenic microbial nucleic acids with no errors. The Panel can identify viruses, bacteria, fungi, parasites, and pathogenic microorganisms. Genes2Me has taken the Pan Pathogen testing to a next level by accelerating the accuracy that can drastically decrease the time of detection. This can effectively change the entire pathogen testing processes to a great deal.

[bestitmagazine]

Technology News

Technology News IIT-Delhi has developed a device that gives dengue results within an hour and the handheld device also helps in rapid detection of human immunodeficiency virus (HIV), IIT Delhi said. The researchers have tested hundreds of blood samples in collaboration with the ICMR-National Institute of Malaria Research (NIMR), New Delhi. The research work was funded by the IMPRINT India program of the Ministry of Education. The device had been clinically tested in collaboration with the National Institute of Malaria Research, the institute said. "The device provides a sensitive, rapid and field-deployable diagnosis of dengue at the early stage," it added. There are certain common diseases like dengue require rapid diagnosis but conventional diagnostic tools like nucleic acid detection using Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a time-taking process, which requires expensive equipment and reagents. Visit on VarIndia site https://www.varindia.com/ and know more about it.

[healthblogsworld]

MANAGE THE CRISIS OF COVID-19 IN ADVANCE WITH THE USE OF TECHNOLOGY

In this era where we all are busy in our lives, no one has time to look after the clinical efficiency of the workflow, to develop risk management tools to which can assist in identifying the gap during care and then further reducing it, making the documentation process faster and managing it. To curb all these issues an integrated suite is available which is cloud-based which understands the problems faced by physicians and helps in reducing their burden and Athena health providers are always present for providing services that you wish to acquire.

 Athena health group is a prime provider of network-enabled services and is present with well-equipped software which can be used for health-related and medical services present nationwide.

Because of this COVID-19 pandemic, a huge need for ambulatory services and customer-related services had occurred. To deal with the workflow constraint and to establish ease of working all Athena health providers are working hand-in-hand by providing or offering the following services-

ü  With the help of a mobile medical reference app, it offers instant access to the centers which are established for guiding Epocrates.

ü  It releases such software updates which align the existing product structures such as questions related to history, order sets, and many more.

ü  Ensures in linking commercial test labs related to COVID-19 to the Athena health services so that they can be present or available nationwide and in some specific states.

ü  To make such an enhanced schedule online through which patients can book their appointments, will further help to minimize the burden on the staff of the hospitals.

ü  This ensures deep partnership in activating its surroundings or ecosystems with prime or major telehealth companies which further manage the patients and their triage.

To guide the healthcare providers a guidance manual known as CDC has been formulated which assist all the healthcare providers and guides them in consonance with the CDC guidance. With the help of this guidance, with the help of only a mobile device a real-time status of the situation of the patient is provided.  

The Athena Health services work in coordination with commercial labs by which an electronic order is generated from the Athena clinic because of which the Athena health providers can directly without following a cumbersome process can order COVID-19 tests as per their normal ordering workflow. The providers can order tests from some of the labs such as:

LabCorp 

Quest     Diagnostics which also launched the RT-PCR test service 

Other     commercial labs

This will not only provide easily test availability to the patients but the providers as well with the medium of Athena health network.

Because of this pandemic, the situation has become worst, and to deal with this crisis it is extremely necessary to take such a step-through which we can help those who are in actual need. In this ecosystem, Athena health has activated a connectivity network between its telehealth partners and its customers to support them or the Athena health providers on the front lines of this pandemic.

To ease the burden on the staff this also provides the schedule of the online patient, patient can also visit personally, the reason for his visit will also be included there. This will minimize the administrative burden and prepare everyone in advance and make them ready to receive the patients who have COVID-19 symptoms and give them time and intimate them early so that they can take early precautions which are extremely needed in this crisis and to act safely. 

If anyone is looking for an ecosystem that is sustainable and high-quality healthcare then Athena is for them only.

[covid19nearme]

COVID-19 Testing Near Me In Westbury

e

We know that you want safe, fast, and accessible COVID-19 testing. So come to our brand-new testing site in Westbury (in front of The Cheesecake Factory) for all of your Corona-virus-related health and safety needs.

All of our Coronavirus testing sites offer touch-less online registration. We are bringing clean, outdoor testing stations to your neighborhood. Now, you can receive local coronavirus testing without the trip!

COVID Testing Site In Westbury (in front of The Cheesecake Factory)

Statcare is bringing you a new coronavirus testing center in Westbury, New York to serve the following areas:

Mineola, Carle Place, Westbury, New Cassel, Old Westbury, Garden City, Williston Park, Roslyn Heights, East Meadow, Hempstead and Uniondale.

Start Appointment Process

Coronavirus Testing Sites In Westbury, New York

Location: 1500 Old Country Road, Westbury, NY 11590

(Located in front of The Cheesecake Factory directly facing Old Country Road)

Testing Hours:

Mon-Fri: 10AM to 7PM Sat-Sun: 10AM to 7PM

To register, start the appointment process by clicking below.

Make an Appointment Today

COVID Tests Now Available at Our Westbury Testing Site:

Antigen (Rapid) COVID-19 Test

After using a simple nasal swab, you can get your test results back as quickly as 15 minutes. This type of test is permitted for use by the Food and Drug Administration (FDA) with an emergency use authorization (EUA). To get more information on how the rapid test works, see Rapid COVID-19 Test Near Me in Westbury.

COVID-19 RT- PCR (Standard) Test

The Polymerase Chain Reaction (PCR) test is intended to diagnose whether an infection is caused by SARS-Cov-2 with a nasal swab sample. Visit our information page for more about the COVID-19 PR-PCR Test available for residents of Westbury.

The COVID-19 Antibody Test

With the COVID-19 Antibody Test, we can detect the presence of Immunoglobulin G (IgG), the antibody that shows that you've previously been exposed to COVID. Performing the COVID-19 antibody test requires a blood sample. You can learn more about the COVID-19 Antibody Test available to Westbury residents by visiting our page.

Looking for a COVID Clinic Nearby?

Easily Find a Statcare Urgent Care Near Me In Westbury

All of Statcare’s mobile vehicle, quick-build, and permanent testing sites are safe, clean, and accessible. We’re doing everything we can to offer convenient coronavirus testing in your neighborhood, without long lines. Statcare accepts all insurance plans for COVID-19 testing. Even if you are uninsured, if you present a valid NY State Driver’s License, you can get your test at no cost.

Just drive right up to any of our testing sites and scan the displayed QR Code on your mobile device to get started. You can also quickly schedule an appointment by clicking here.

If you need some help signing up, please contact one of our live agents by using the chat box provided below. You can also complete our contact form, and one of our representatives will follow up with you.

Statcare’s Ongoing Coronavirus Pandemic Efforts

We always follow CDC, WHO, and FDA guidance and counseling with all of our COVID-19 protocols. For a complete list of coronavirus symptoms, visit the CDC website and check it against any signs you might be experiencing.

From the start of this pandemic, Statcare has provided efficient and effective testing choices for symptomatic patients, helping them detect coronavirus without close contact. As of December, we’ve already conducted over 60,000 COVID-19 PCR tests in New York, as dictated by the state’s health department. We are also staying at the frontlines of the process to bring you the coronavirus vaccine as soon as it is available.

Now that we’ve taken COVID-19 testing on the road, that’s expanded the options we are bringing to you. Statcare offers coronavirus testing options right in your backyard, from our new testing site in Westbury. Our mobile and temporary COVID-19 test sites also serve Westhampton, Quogue, Easthampton, Southampton, Hampton Bays, Riverhead, Bridgehampton, and Northampton.

Come and Get Your Coronavirus Test in Westbury Today!

You can get your test at Statcare’s newest open-air COVID-19 facility, now open in Westbury.New York. Reduce the risk of contact and help minimize coronavirus spread. Avoid standing in long lines or crowded waiting rooms by choosing Statcare. With our convenient and accessible coronavirus testing, you can join us in helping prevent the spread of COVID-19.

Statcare always follows the guidelines passed down by the Centers for Disease Control and Prevention and NYS Department of Health. If you are symptomatic, schedule your test to get evaluated faster. At Statcare, we always accept walk-in patients and strive to offer safe, hassle-free testing, providing safety and security for all.

Statcare Coronavirus Tests are Available In Westbury

Start Your Appointment Process Today!

OUR LOCATIONS

Telehealth Visit

Online Doctor Appointment Virtual doctor on call service

SAVE MY SPOT

Hicksville, New York

232 W. Old Country Road Hicksville, NY 11801 Mon – Fri: 8 am – 8 pm Sat – Sun: 9 am – 5 pm Holidays: 9 am – 3 pm

Astoria, Queens

37-15 23 rd, Avenue Astoria, NY 11105 Mon – Fri: 8 am – 8 pm Sat – Sun: 9 am – 5 pm Holidays: 9 am – 3 pm

Bronx, (174TH ST)

932 East 174th Street Bronx, NY 10460 Mon – Fri: 8 am – 8 pm Sat – Sun: 9 am – 3 pm Holidays: 9 am – 3 pm

Bronx, (Bartow)

2063A Bartow Avenue Bronx, NY 10475 Mon – Fri: 9 am – 9 pm Sat: 9 am – 5 pm Sun: 9 am – 3 pm Holidays: 9 am – 3 pm

Brooklyn

341 Eastern Parkway Brooklyn, NY 11216 Mon – Fri: 8 am – 9 pm Sat – Sun: 9 am – 5 pm Holidays: 9 am – 3 pm

Jackson Heights

80-10 Northern Boulevard Jackson Heights, NY 11372 Mon – Fri: 9 am – 9 pm Sat – Sun: 9 am – 5 pm Holidays: 9 am – 3 pm

Midtown Manhattan

715 9th Avenue Suite 1 New York, NY 10019 Mon – Fri: 8 am – 8 pm Sat – Sun: 9 am – 5 pm Holidays: 9 am – 3 pm

Jamaica

90-18 Sutphin Blvd Jamaica, NY 11435 Mon – Fri: 9 am – 7 pm Sat: 9 am – 5 pm Sun: 9 am – 2 pm Holidays: 9 am – 3 pm

(917) 920-7321

Real-Time Customer Reviews

[internal_pages_output]

SEE ALL REVIEWS

Sign Up For Email OffersSign up to receive coupons, health tips, and more–directly to your inbox.

Your Name (required)

Your Email (required)

QUICK LINKS

Urgent Care Insurances Accepted

Our Services

Patient Resources

Contact Us

Code of Conduct

Privacy Policy

DOC TALKS BLOG

New Variant COVID Strain: New Normal to New Nightmare

COVID Vaccine: The Race to Save Lives

7 Signs a Free COVID Test in New York is Legit

5 Covid-19 Pop-Up Testing Sites You Need To Know About

Copyright © 2020 STATCARE URGENT & WALK-IN MEDICAL CARE. ALL RIGHTS RESERVED. Billing Address: STATCARE URGENT & WALK-IN MEDICAL CARE 17 E OLD COUNTRY RD, UNIT 305, HICKSVILLE, NY 11801

TWITTER  /  FACEBOOK  /  INSTAGRAM  /  LINKEDIN  /  YOUTUBE

If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact Shared Suri at service@statcarewalkin.com or by phone at (917) 920-7321 Extension 288.

[cedar-glade]

Extended cell access and targetting summerized in light reading detail, and current issues with fast test methods(Expansive reasons for false negatives/positives aside from asymptomatic exposures) This does not include a summery on Spike light and heavy chain mutation and RNA replication transposon insertion mutation. This also does not include the current treatment protocal and the current concepts inline with UMAP analysis and Proteomic prompts.

Covid- 19 review and Associated Fast Treatment Methods Review

John Potter/ 05/ 07/ 2020 

 COVID-19(SARS COV 2), a member of the corona virus family, Coronaviridae, and a linked relative to the original SARS- COV, is an airborne pathenogenic retro virus; “Coronaviruses (CoVs), enveloped positive-sense RNA viruses, are characterized by club-like spikes that project from their surface, an unusually large RNA genome” (Fehr, Perlman et. al. 2015)(WHO, 2020). While airborne transmission is the open cause and primary cause noted it may not explain the mechanism in full; “Human-to-human transmission is primarily achieved through close contact of respiratory droplets, direct contact with the infected individuals, or by contact with contaminated objects and surfaces”(Malik Ya, 2020).  COVID-19 is named this due to it’s Chinese origin and the year it was isolated but it’s legitimized name in virology is SARS COV 2(WHO, 2020). It functions as a primary pathogenetic virus that effects immune response and becomes more damaging in the presence of a secondary pathogen (such as bacteria that cause pneumonia), or in immunocompromised subjects (Zheng et. al. 2020) (Leng et. al. 2020). It functions by causing irritation, over production of mucus, and inflammation in direct correlation to infection of specific cell tissues in the upper lower respiratory tract, “mainly invades alveolar epithelial cells” (Zheng et. al. 2020). The mode of infection mechanisms works by targeting specific cells in the respiratory tract that are ACE2 heavy, progenitor cells that may be peripheral primordia or end up elongating into cilia cells that clean debris from lungs(WHO, 2020)(Zheng et. al. 2020). Other specified areas of respiratory periphery cells responsible to upkeep that can also have serious detrimental effects after infection are found in the bronchii; “bronchial transient secretory cells” (Lukassen et. al. 2020).  “ACE2 is the main host cell receptor of 2019 CoV and plays a crucial role in the entry of virus into the cell to cause the final infection” ( Xu. et. al. 2020). “Angiotensin-converting enzyme 2 (ACE2) is a membrane-bound aminopeptidase that has a vital role in the cardiovascular and immune systems” (Zheng et. al. 2020). COVID-19 opperates specifically systematically binding a part of the primary antigen spike protein of the virus to ACE2 and entering the tissues present, which are mainly in the lungs and cardiovascular system (Zheng et. al. 2020).

 ACE 2 mechanisms function as receiving the spike protein of Sars Cov 2, SARS-S,  and then binding, a second signaling event and conformational change event for cell access of the virus occurs from protein cleavage/priming of a protease(Hirano and Mirikami 2020). Transmembrane acceptance protein protease or specifically, “Type II transmembrane serine proteases TMPRSS2 and HAT can cleave and activate the spike protein (S) of the severe acute respiratory syndrome coronavirus (SARS-CoV) for membrane fusion” (Huerich et. al. 2013). This is done by opening up the antigen embedded in the viral lipid membrane and by opening up ACE2, angiotensin-converting enzyme 2, in similar fashion of the host cell membrane (Huerich et. al. 2013)( Hirano and Mirikami 2020). Because of this feature, it is also potentially of interest to study specific protease inhibitors to manage treatment, “A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option” ( Hirano and Mirikami). Once inside, a COV follows a set of criteria for self-preservation: Conserve genomic organization “with a large replicase gene preceding structural and accessory genes … expression of many non-structural genes by ribosomal frameshifting;… utilize several unique or unusual enzymatic activities encoded within the large replicase–transcriptase polyprotein; and utilize expression of downstream genes by synthesis of 3′ nested sub-genomic mRNAs”(Fehr and Perlman et. al. 2015).

-H-COV integration, and with this specific case in mind, is derived from the RNA in the capsule; “within the helically symmetrical nucleocapsid is the large positive sense, single stranded RNA” where RNA is ejected via motor protein into the cellular matrix of cytoplasm( Malik Ya, 2020). After insertion RNA replication and translation needs to occur on a vast scale before lysing and eruption into mucus can occur properly (Malik Ya, 2020).

“Translation of the replicase gene from the virion genomic RNA and then translation and assembly of the viral replicase complexes is done first; following, replication and subgenomic RNA synthesis, encapsidation occurs resulting in the formation of the mature virus”(Malik Ya, 2020). The “nested” three prime end of the viral RNA contains critical coding information for this all to proceed (Malik Ya, 2020)(Fehr and Perlman et. al. 2015). The major structural proteins are noted as such: “the spike (S), membrane (M), envelope (E) and the nucleocapsid (N) protein” (Malik Ya, 2020).  Clarity on the other structural proteins mentioned besides the S protein mentioned above can also be found in Dr. Malik Ya’s review:

“The M protein is the most abundant protein and defines the shape of the viral envelope. The E protein is the smallest of the major structural proteins and participates in viral assembly and budding. The N protein is the only one that binds to the RNA genome and is also involved in viral assembly and budding…”

Once this virus takes out these cells, other infections make use of the issues caused by a lack of lung up keep and excess mucus: Pneumonia is a secondary infection that seems to be one of the more detrimental for example (Lukassen et. al. 2020) (WHO, 2020) (Zheng et. al. 2020). This seems to be why the virus is so deadly, easily expressed, and transported from human-human with such vigor. This is also why a stay at home order, cleanliness, and social distancing is very critical(WHO, 2020).

 COVID-19 can be testable in several ways, for rapid test examples, kits for ELISA, and other fast antigen tests are used frequently. Although ELISA tests can show the presence of COV-19 if a patient is in symptomatic stages as a confirmation, the issue lies in the fact that a patient may not contain anti-bodies in their serum for up to ~2 weeks or a week and a half, that are antigen specific (BIORAD, 2020). This usually is not a problem since symptoms arise within the first two weeks; but, in early testing scenarios this is problematic as there might be potential for a false negative. ELISA’s are incredibly fast though and extremely simple to train for and preform for newer medical professionals or volunteers. ELISA well sterility and cleaning procedures is also very critical to mitigate the likely hood of a false positive color change from previous contamination (BIORAD, 2020). Another rapid test is COVID-19 IgG/IgM Rapid Test; “ is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 novel coronavirus in human whole blood, serum or plasma” (AYTU BIOSCI, 2020). This test is another 2-10 minute rapid test; but is considerably more complex and also requires antigen to be present in serum(AYTU BIOSCI, 2020).

With RT-PCR(Reverse Transcriptase, Polymerase Chain Reaction), it is much safer to fully commit on analysis if swabs are done properly. RT-PCR does not use antigen recognition instead, “RNA molecules are first converted into complementary DNA (cDNA) molecules that can then be amplified by PCR” and conserved targeting sequences(J.L. Jones, 2015). Viruses present in mucus swabs are critical in providing a positive or negative result, swabs from elsewhere with no respiratory mucus present may cause false negatives. These tests can detect influenza viral RNA or nucleic acids in respiratory specimens with high sensitivity and high specificity(conserved gene targets) in 20-30 minutes (CDC, 2019). Following directions for transport of specimen, swab type, and other procedure is critical for real results( CDC,2019).  If viruses aren’t being shed, sometimes not enough may be present before symptoms, this test may also create false negatives (CDC, 2019). Another clear fall through with RT- PCR is availability of devices and kits capable of RT-PCR and expenses when compared to the accessibility of other assay(CDC, 2019). In this way, they each server their purpose as being fast, and accessible or being more accurate and still relatively quick. I say relatively because older RT-PCR systems can take multiple days to finish( J. L. Jones, 2015).

Work Cited:

 Journal Articles, R.A., and Online Journal Articles:

Adeline, H. et. al. “TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein.” Dec. 2013. Journal of Virology ,88 (2) 1293-1307. DOI: 10.1128/JVI.02202-13.

Fehr, A. and Perlman, S. et. al. “Coronaviruses: An Overview of Their Replication and Pathogenesis.” 12, February. 2015. Coronaviruses; 1282: 1–23. doi: 10.1007/978-1-4939-2438-7_1

Hoffman, M. et. al. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.”16, April. 2020. CELL. Volume 181, Issue 2, Pages 271-280.e8 https://doi.org/10.1016/j.cell.2020.02.052

Hoffman, M. et. al. “The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells.” 2020. BIORXIV. https://doi.org/10.1101/2020.01.31.929042

Huang, S. et. al. “SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes.” 23, April. 2020. Nat Med 26, 681–687. https://doi.org/10.1038/s41591-020-0868-6

J.L. Jones, “On Reverse Transcription PCR”. High Throughput Screening for Food Safety Assessment, 2015. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/reverse-transcription-polymerase-chain-reaction

Leng, Z. et. al. “Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.”2020. Aging and Disease , Vol. 11 Issue (2): 216-228. DOI:10.14336/AD.2020.0228

Leung et. al. “ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19.” 2020. European Respiratory Journal; DOI: 10.1183/13993003.00688-2020

Lukassen, S. “SARS‐CoV‐2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells.” 14, April. 2020. EMBO J e105114. https://doi.org/10.15252/embj.20105114

Prompetchara, E. Ketloy, C. and Palaga, T. “Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.” 2020. Asian Pacific Journal of Allergy and Immunology. R.A. ;38:1-9 DOI 10.12932/AP-200220-0772

Ya, Malik. “Properties of Coronavirus and SARS-CoV-2.” April. 2020. Malays J Pathol ;42(1):3-11. https://www.ncbi.nlm.nih.gov/pubmed/32342926

Xu, H., Zhong, L., Deng, J. et al. “High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa.” 2020. Int J Oral Sci 12, 8 https://doi.org/10.1038/s41368-020-0074-x

Zheng, Y. et. al. “COVID-19 and the cardiovascular system.” 05, March. 2020. Nat Rev Cardiol 17, 259–260. https://doi.org/10.1038/s41569-020-0360-5

Government PDF Sources:

“Coronavirus disease 2019 (COVID-19) Situation Report – 67.” 27, March. 2020. World Health Organization(WHO).

“Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations.” 27, March. 2020. World Health Organization(WHO).

Website sources:

“Coronavirus Test Update: COVID-19 IgG/IgM Rapid Test.” AYTU BIOSCIENCE. 2020. https://aytubio.com/covid-19/

“Information on Rapid Molecular Assays, RT-PCR, and other Molecular Assays for Diagnosis of Influenza Virus Infection.” CDC. October, 21, 2019. https://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm

“What is ELISA?: An Introduction to ELISA.” BIORAD. 2020. https://www.bio-rad-antibodies.com/an-introduction-to-elisa.html

[disposablegowns]

Introduction and Status of Nucleic Acid Extractor

A nucleic acid extraction instrument is an instrument that automatically completes the extraction of sample nucleic acid by using the matching nucleic acid extraction reagent. The nucleic acid extraction instrument is divided into two categories: one is large-scale automation, generally called automatic liquid workstation; the other is small The automatic nucleic acid extractor uses packaged supporting reagents to automatically complete the extraction and purification process. Because of the high equipment cost and high operating cost, large-scale automatic liquid workstations are suitable for extracting thousands of samples of the same type at a time, so they are rarely used; while small automated instruments are more and more convenient to operate because of low equipment and operating costs. more applications.

Nucleic acid extraction instrument application fields:

In almost every laboratory, the separation and purification work related to biomolecules is very important and indispensable. However, it is quite difficult to purify multiple samples, not only need to choose the appropriate purification technology but also the workload is very large, and it is difficult to meet the current rapid development of high-throughput sample extraction and purification needs.

Features of Nucleic Acid Extractor:

Cooperate with the independent sub-packaging reagent for extracting a single sample. During the operation process, only the sample action needs to be added, and the instrument automatically completes the whole process of extraction and purification without adding the reagents required in the extraction process. It is a small automatic nucleic acid extraction that has really been applied. instrument.

All Chinese display, easy to use.

1 Precise control

Built-in engineering computer, no need to connect a personal computer; stand-alone operation saves more space and energy and provides a high-stability automatic control system.

2 Free Programming

Powerful program editing function; define your application flexibly and efficiently to meet different reagent requirements.

3 Quick extraction

The operation time is short, 30-60 minutes per time; the appropriate amount is large, and 1-20 samples can be extracted at the same time each time.

4 High purity and high yield

The purification scheme can be optimized according to the reagents to achieve higher extraction efficiency, and the extracted DNA/RNA has high purity and can be directly used for PCR and RT-PCR.

5 Results are stable

Avoid differences and errors caused by manual operation, and the result is temperature and repeatability.

6 Reagents open

Various magnetic bead extraction reagents are available.

7 Safe, reliable, and low cost

Closed extraction chamber, disposable consumables, minimize operator contact with reagents; low cost.

SIGNO GROUP TECHNOLOGY CO., LTD. is located in Chuangxuan Industrial Park, Shenzhen. Mainly produces and sells various medical device products, including disposable protective masks, KN95, FFP2 protective masks, disposable nitrile gloves, disposable medical nitrile examination gloves, nitrile blend gloves, disposable vinyl protective gloves, and medical protective gloves clothing, disposable isolation gowns, surgical gowns, and nucleic acid extraction instruments. If you want to know more about the materials of disposable medical protective clothing, you can contact us at SIGNO, we are a professional manufacturer of disposable medical protective clothing, dedicated to producing high-quality disposable medical protective clothing for our customers. Welcome to contact us.

[pathologylab]

#G2M's EGFR-Q Real-Time PCR Kit is an in vitro #diagnostic test intended for the qualitative #detection of #EGFR mutations in genomic #DNA extracted from fresh, frozen or formalin-fixed paraffin-embedded (FFPE) tissue. It is designed to selectively detect 21 different mutations across four exons i.e. exon 18, 19, 20, 21 for changes in EGFR #gene in tumor tissue.

Visit our website for more information. https://www.genes2me.com/ivd-real-time-pcr-test-kits/oncology-diagnostic-kit

For more details, Call us at +91-8800821778 or drop us an email at social@genes2me.com

#RTPCR #EGFR #Lungcancer #pcr #Genes2me #testing #kits #solutions #madeinindia #india #manufacturer #poct #ivd